Bedrijfsoverzicht
Galmed Pharmaceuticals Ltd. is a biopharmaceutical entity dedicated to the development of therapeutic solutions specifically targeting the treatment of liver diseases. The company operates within the healthcare sector, more precisely in the biotechnology industry, which implies a focus on high-risk, high-reward research and development of novel medical treatments. Galmed's current operational scale is characterized by a very small market capitalization of $4.89M and a workforce consisting of only three employees. These figures indicate that Galmed is a micro-cap company with minimal revenue generation, reflecting its early-stage position where the majority of resources are likely allocated toward research rather than commercial sales or extensive infrastructure. The extremely low employee count alongside a significant cash reserve suggests the company is in a capital-intensive development phase where human capital is currently concentrated in key scientific roles rather than broad administrative expansion. This lean structure is typical for biotechnology firms in Phase III studies that have not yet achieved substantial commercial product launch or widespread market penetration.
Financiële gezondheid
The company reports a Net Income of $-10,309,000 and an EBITDA of $-8,427,000 over the trailing twelve months, while the Revenue figures are not available due to the N/A status in the provided data. The substantial gap between the reported Net Income loss and the EBITDA loss highlights the impact of significant non-operating expenses, likely including R&D costs, stock-based compensation, or other corporate overheads that are deducted after operating profits are calculated. Galmed's Free Cash Flow stands at $-3,828,125, indicating that the company is burning through cash reserves to fund its operations and development pipeline rather than generating cash from its current business activities. Despite this negative cash flow, the company holds a robust Cash balance of $18.16M, which provides a significant runway for operations before capital conservation becomes critical. The balance sheet appears conservative regarding leverage, as the company reports zero Debt against a Cash position, resulting in a Debt to Equity ratio that is not applicable (N/A) due to the lack of equity or debt obligations. Furthermore, the Current Ratio is reported at 6.55, a metric that signifies an extremely strong short-term liquidity position, suggesting the company has more than enough current assets to cover its short-term liabilities. The Return on Equity is a negative 64.2% and the Return on Assets is negative 28.7%, metrics that reveal that the company's current management efforts and asset utilization are resulting in value destruction rather than value creation at this specific point in time.
Waarderingsbeoordeling
The Trailing Twelve Months P/E Ratio is not applicable (N/A) because the company is unprofitable, while the Forward P/E stands at -0.72, a figure that implies earnings are expected to be negative in the near future or that the market is pricing in a scenario where losses may persist or widen. The Price to Book ratio is 0.21, which indicates that the stock is trading at a significant discount to its book value, suggesting the market values the company's tangible assets at less than twenty percent of their accounting value. Since the Price to Sales ratio is N/A, traditional revenue-based valuation multiples cannot be applied, but the EV/EBITDA multiple is 1.58, a metric that offers an alternative perspective on valuation relative to earnings before interest, taxes, depreciation, and amortization. The stock has demonstrated significant price volatility within the past year, trading between a 52-Week High of $2.68 and a 52-Week Low of $0.41. Relative to this range, the current valuation sits within the lower half of the trading band, reflecting the high risk premium associated with small-cap biotechnology stocks. The Beta value is 0.47, which indicates that the stock's price volatility is less than that of the broader market, moving at a slower pace than the S&P 500 on average. This lower beta suggests the stock may be less sensitive to general market swings, though its specific risk profile is dominated by the binary outcomes of its drug development program.
Growth & Income
The company's Revenue Growth and Earnings Growth for the year-over-year period are both listed as N/A, meaning there are no historical data points to determine the rate at which earnings are growing faster or slower than revenue. Galmed Pharmaceuticals does not distribute dividends to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. The absence of a dividend payout confirms that the company follows a strategy of reinvesting all available earnings and cash reserves directly into research and development rather than returning capital to investors. This growth-focused approach is standard for biotechnology companies that rely on funding their Phase III studies and future product launches to achieve profitability. Consequently, the overall growth and income profile of Galmed is defined by potential future expansion rather than current income generation, leaving investors without a yield stream to offset the high risk of the underlying biotechnology venture.